ClinicalTrials.gov recorded primary completion on 31 August 2026 for a Phase 3 trial of pembrolizumab as adjuvant therapy for triple-negative breast cancer. The randomized study enrolled 1,155 participants and remained active, not recruiting, according to the supplied record. No outcome measurements or treatment results were provided.
Background
The study evaluates pembrolizumab, also identified in the record as MK-3475, in patients with triple-negative breast cancer. The trial’s listed conditions include breast carcinoma in situ, invasive breast carcinoma, and stage I, II, and III breast cancer under specified AJCC versions. Its stated purpose is to study how well pembrolizumab works as adjuvant therapy in this setting.
The registry describes pembrolizumab as an immunotherapy involving monoclonal antibodies. It states that this approach may help the body’s immune system attack cancer and may interfere with tumor cells’ ability to grow and spread. The supplied data do not provide additional mechanism details, prior approvals, or prevalence figures.
Trial design
This was a Phase 3 randomized trial studying pembrolizumab in patients with triple-negative breast cancer. The study enrolled 1,155 participants and listed pembrolizumab as its intervention. The ClinicalTrials.gov record gave the overall status as active, not recruiting at the time represented in the supplied data.
The record’s brief summary says the trial was designed to assess pembrolizumab as adjuvant therapy. Although the study was randomized, the supplied data do not identify a comparator arm, dosing schedule, treatment duration, or a specific primary endpoint.
What this means
Primary completion indicates that the registry recorded the study’s primary completion event on 31 August 2026. The event confirms the stage and scope of the clinical investigation, but it does not by itself establish whether pembrolizumab improved outcomes for patients with triple-negative breast cancer.
No primary outcome entries, key measurements, statistical analyses, p-values, confidence intervals, or adverse-event summary were supplied. The available information therefore does not show treatment efficacy, comparative safety, or a change in pembrolizumab’s approved use.
Source
Source: ClinicalTrials.gov, clinical trial registry record for “Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer,” NCT02954874, with the primary-completion event dated 31 August 2026. The record is available at clinicaltrials.gov/study/NCT02954874.